Pfizer Inc. raised its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that reflects the preference many governments have for the shot over rivals.
The New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses and are working with other firms overseas to produce doses.
